Hint mode is switched on Switch off
For swift navigation between sections

Organization: Ligand
LEI 5493008K7TB0IKP37H79

Organization name
Ligand Pharmaceuticals, Inc
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Bond debt
-

explore the most comprehensive database

800 000

bonds globally

Over 400

pricing sources

80 000

stocks

9 000

ETF

track your portfolio in the most efficient way
Bond Search
Watchlist
Excel ADD-IN
Get access
×

— Are you looking for the complete & verified bond data?

— We have everything you need:

full data on over 700 000 bonds, stocks & ETFs; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available anywhere via Website, Excel Add-in and Mobile app.

Register
×

Why

You will have detailed descriptive & pricing data for 650K bonds, 76K stocks, 8K ETFs
Get full access to the platform from any device & via Cbonds app
Enhance your portfolio management with Cbonds Excel Add-in
Build yield maps, make chart comparison within a click
Don't wait any longer — start using Cbonds today! Register

Latest data on

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Ligand Pharmaceuticals Incorporated (Ligand) is a biotechnology company that operates with a business model focused on developing or acquiring assets. The Company’s technology portfolio CAPTISOL is a formulation technology that has enabled five Food and Drug Administration (FDA) approved products, including Pfizer’s VFEND IV and Baxter International’s Nexterone and is being used in a number of clinical-stage partner programs. The therapies in its portfolio in development address the unmet medical needs of patients for a spectrum of diseases, including hepatitis, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, asthma, rheumatoid arthritis and osteoporosis. It’s wholly owned subsidiaries include Ligand JVR, Allergan Ligand Retinoid Therapeutics, Seragen, Inc., Pharmacopeia, LLC, Neurogen Corporation, CyDex Pharmaceuticals, Inc. and Metabasis Therapeutics. 

Awards

News

17/04/2024 Ligand: Amendments To Articles Of Incorporation Or Bylaws; Change In Fiscal Year, Financial Statements And Exhibits
27/02/2024 Ligand: Results Of Operations And Financial Condition, Financial Statements And Exhibits
05/01/2024 Ligand: Other Items
29/11/2023 Ligand: Enter Into A Material Definitive Agreement
09/11/2023 Ligand: Results Of Operations And Financial Condition, Financial Statements And Exhibits
All organization news

Documentation

IFRS/US GAAP reports

2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Latest issues

Show all

Bond debt by currency

Show more Hide

Codes

  • LEI
    5493008K7TB0IKP37H79
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • CIK
    0000886163
  • EIN
    77-0160744

Credit and ESG Ratings

Macroeconomic Indicators - Ligand

Registration is required to get access.